Artax Biopharma Inc

Artax Biopharma Inc is a development-stage biopharmaceutical company focused on revolutionizing the treatment of autoimmune and inflammatory diseases. With the slogan "Developing oral first-in-class Nck blockers for the treatment of T-cell-mediated autoimmune diseases," the company is dedicated to developing new therapies for these conditions. Founded in 2013, Artax Biopharma is at the forefront of the Biopharma, Biotechnology, and Health Care industries, aiming to address unmet medical needs. The company's innovative approach involves the development of drugs targeting the interaction between TCR and Nck, responsible for T-cell activation. By focusing on specific control over T-cells through TCR, Artax Biopharma's compounds hold the potential to become first-in-class immunomodulators for a diverse range of autoimmune and inflammatory diseases. This unique approach signifies a promising advancement in the field of autoimmune disease treatment. Notably, Artax Biopharma recently secured a significant $26.00MVenture Round investment on 11 May 2022, attracting support from prominent investors including Advent Life Sciences, Columbus Venture Partners, Eli Lilly, Sound Bioventures, and Belinda Termeer. This substantial investment underscores stakeholders' confidence in the company's potential to make a lasting impact in the biopharmaceutical landscape and address the unmet medical needs of patients with autoimmune and inflammatory diseases.